FY2025 · ended Dec 31, 2025 · Revenue $228.37M, -0.9% YoY · Filed Feb 26, 2026
Puma Biotechnology, Inc. (PBYI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $228.4 million and net income of $31.1 million. Free cash flow was $41.7 million. As of Jun 30, 2026 it held $93.9 million in cash and investments and $4.8 million in total debt.
Revenue (TTM)
$231.24M
-2.9% vs year-ago TTM
Net income (TTM)
$26.72M
-44.9% vs year-ago TTM
Operating cash flow (TTM)
$41.15M
-7.2% vs year-ago TTM
Free cash flow (TTM)
$41.14M
-7.0% vs year-ago TTM
EPS (TTM)
$0.52
-46.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
50.88M
+2.6% vs prior year
Net cash
$89.09M
as of Jun 30, 2026
Operating margin
13.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PBYI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1401667
- Former names
- INNOVATIVE ACQUISITIONS CORP (until Oct 4, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M | $253.2M |
| Operating income | $37.3M | $31.0M | $32.6M | $23.7M | $1.3M |
| Net income | $31.1M | $30.3M | $21.6M | $2,000 | -$29.1M |
| Diluted EPS | $0.61 | $0.62 | $0.45 | $0.00 | — |
| Operating cash flow | $41.8M | $38.9M | $27.0M | -$15.8M | $20.6M |
| Free cash flow | $41.7M | $38.9M | $26.9M | -$15.8M | $20.6M |
| Total assets | $216.3M | $213.3M | $230.5M | $222.1M | $226.6M |
| Total liabilities | $86.0M | $121.2M | $177.1M | $200.5M | $229.0M |
| Stockholders' equity | $130.3M | $92.1M | $53.4M | $21.6M | -$2.4M |
| Cash and investments | $97.5M | $101.0M | $95.9M | $81.1M | $82.1M |
| Total debt | $28.7M | $75.0M | $113.8M | $118.0M | $121.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 28, 2026 | Dec 31, 2025 |
All 1000 Puma Biotechnology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.